Search

Your search keyword '"Vascular Access Device"' showing total 3 results
Start Over Descriptor "Vascular Access Device" Journal cancer medicine
3 results on '"Vascular Access Device"'

1. Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first‐line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)

Author

Ben Tran, Jose M. Ruiz‐Morales, Enrique Gonzalez‐Billalabeitia, Anna Patrikidou, Eitan Amir, Christoph Seidel, Carsten Bokemeyer, Christian Fankhauser, Thomas Hermanns, Alexey Rumyantsev, Alexey Tryakin, Margarida Brito, Aude Fléchon, Edmond Michael Kwan, Tina Cheng, Daniel Castellano, Xavier Garcia del Muro, Anis A. Hamid, Margaret Ottaviano, Giovannella Palmieri, Robert Kitson, Alison Reid, Daniel Y. C. Heng, and Philippe L. Bedard more...

Subjects
deep vein thrombosis, germ cell tumor, pulmonary embolism, testicular cancer, vascular access device, venous thromboembolism, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Metastatic germ cell tumor (mGCT) patients receiving chemotherapy have increased risk of life‐threatening venous thromboembolism (VTE). Identifying VTE risk factors may guide thromboprophylaxis in this highly curable population. Methods Data were collected from mGCT patients receiving first‐line platinum‐based chemotherapy at 22 centers. Predefined variables included International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification, long‐axis diameter of largest retroperitoneal lymph node (RPLN), Khorana score, and use of indwelling vascular access device (VAD). VTE occurring at baseline, during chemotherapy and within 90 days, was analyzed. Results Data from 1135 patients were collected. Median age was 31 years (range 10‐74). IGCCCG risk was 64% good, 20% intermediate, and 16% poor. VTE occurred in 150 (13%) patients. RPLN >3.5 cm demonstrated highest discriminatory accuracy for VTE (AUC 0.632, P more...

Published
2020
Full Text
View/download PDF

2. Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first‐line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3).

Author

Tran, Ben, Ruiz‐Morales, Jose M., Gonzalez‐Billalabeitia, Enrique, Patrikidou, Anna, Amir, Eitan, Seidel, Christoph, Bokemeyer, Carsten, Fankhauser, Christian, Hermanns, Thomas, Rumyantsev, Alexey, Tryakin, Alexey, Brito, Margarida, Fléchon, Aude, Kwan, Edmond Michael, Cheng, Tina, Castellano, Daniel, Garcia del Muro, Xavier, Hamid, Anis A., Ottaviano, Margaret, and Palmieri, Giovannella more...

Subjects
TERATOCARCINOMA, GERM cells, GERM cell tumors, CANCER cells, THROMBOEMBOLISM, SURGICAL arteriovenous shunts
Abstract

Background: Metastatic germ cell tumor (mGCT) patients receiving chemotherapy have increased risk of life‐threatening venous thromboembolism (VTE). Identifying VTE risk factors may guide thromboprophylaxis in this highly curable population. Methods: Data were collected from mGCT patients receiving first‐line platinum‐based chemotherapy at 22 centers. Predefined variables included International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification, long‐axis diameter of largest retroperitoneal lymph node (RPLN), Khorana score, and use of indwelling vascular access device (VAD). VTE occurring at baseline, during chemotherapy and within 90 days, was analyzed. Results: Data from 1135 patients were collected. Median age was 31 years (range 10‐74). IGCCCG risk was 64% good, 20% intermediate, and 16% poor. VTE occurred in 150 (13%) patients. RPLN >3.5 cm demonstrated highest discriminatory accuracy for VTE (AUC 0.632, P <.001) and was associated with significantly higher risk of VTE in univariable analysis (22% vs 8%, OR 3.0, P <.001) and multivariable analysis (OR 1.8, P =.02). Other significant risk factors included, Khorana score ≥3 (OR 2.6, P =.008) and VAD use (OR 2.7, P <.001). Conclusions: Large RPLN and VAD use are independent risk factors for VTE in mGCT patients receiving chemotherapy. VAD use should be minimized in this population and thromboprophylaxis might be considered for large RPLN. [ABSTRACT FROM AUTHOR] more...

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results

3. Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first‐line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)

Author

Xavier Garcia del Muro, Alexey Tryakin, Anis A. Hamid, Daniel Castellano, Philippe L. Bedard, Enrique Gonzalez-Billalabeitia, Anna Patrikidou, Tina Cheng, Giovannella Palmieri, Carsten Bokemeyer, Robert Kitson, Christian D. Fankhauser, Christoph Seidel, Edmond M. Kwan, Margarida Brito, Margaret Ottaviano, Aude Flechon, Thomas Hermanns, Daniel Y.C. Heng, Eitan Amir, Jose Manuel Ruiz-Morales, Alison Reid, Alexey Rumyantsev, Ben Tran, University of Zurich, and Tran, Ben more...

Subjects
0301 basic medicine, Male, Cancer Research, pulmonary embolism, medicine.medical_treatment, Gastroenterology, 0302 clinical medicine, Catheters, Indwelling, Risk Factors, Antineoplastic Combined Chemotherapy Protocols, 1306 Cancer Research, Child, Original Research, education.field_of_study, Middle Aged, Neoplasms, Germ Cell and Embryonal, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Pulmonary embolism, testicular cancer, Oncology, 030220 oncology & carcinogenesis, Lymphatic Metastasis, 2730 Oncology, Vascular Access Devices, Adult, medicine.medical_specialty, Adolescent, Retroperitoneal Lymph Node, Population, venous thromboembolism, 610 Medicine & health, Risk Assessment, lcsh:RC254-282, deep vein thrombosis, 03 medical and health sciences, Young Adult, vascular access device, Internal medicine, medicine, 2741 Radiology, Nuclear Medicine and Imaging, Humans, Radiology, Nuclear Medicine and imaging, Retroperitoneal Neoplasms, Retroperitoneal Space, cardiovascular diseases, education, Testicular cancer, Aged, Retrospective Studies, Chemotherapy, business.industry, Clinical Cancer Research, germ cell tumor, medicine.disease, 10062 Urological Clinic, 030104 developmental biology, Germ cell tumors, Metastatic Germ Cell Tumor, Lymph Nodes, Cisplatin, business, Venous thromboembolism
Abstract

Background Metastatic germ cell tumor (mGCT) patients receiving chemotherapy have increased risk of life‐threatening venous thromboembolism (VTE). Identifying VTE risk factors may guide thromboprophylaxis in this highly curable population. Methods Data were collected from mGCT patients receiving first‐line platinum‐based chemotherapy at 22 centers. Predefined variables included International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification, long‐axis diameter of largest retroperitoneal lymph node (RPLN), Khorana score, and use of indwelling vascular access device (VAD). VTE occurring at baseline, during chemotherapy and within 90 days, was analyzed. Results Data from 1135 patients were collected. Median age was 31 years (range 10‐74). IGCCCG risk was 64% good, 20% intermediate, and 16% poor. VTE occurred in 150 (13%) patients. RPLN >3.5 cm demonstrated highest discriminatory accuracy for VTE (AUC 0.632, P, Venous thromboembolism can cause morbidity in germ cell tumor patients receiving chemotherapy; large retroperitoneal lymphadenopathy (RPLN) and indwelling vascular access devices (VAD) are significant VTE risk factors. VAD insertion should be avoided and thromboprophylaxis can be considered for large RPLN. more...

Published
2020